BeiGene Seeks Historic Third Listing in Shanghai, Complementing US and HK
The 11-year-old money-losing biotech has filed for a listing on Shanghai’s STAR Market to raise more than $3 billion Key Takeaways: BeiGene will become the world's first stock to be…
RELATED ARTICLES
-
Heated market for dueling blood cancer drugs lands BeiGene in court
BGNE.US 6160.HK
-
Sales success comes with side effects for drug maker BeiGene
BGNE.US 6160.HK
-
BeiGene goes for global growth with sales and R&D push
BGNE.US 6160.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
FAST NEWS: Beigene stock falls after Novartis terminates partnership
BGNE.US 6160.HK
-
‘Sing! China’ flames out, leaving STAR CM in the dark
6698.HK
-
Drug maker Junshi seeks Swiss cure for cash woes
1877.HK 688150.SHG
Discover hidden China stock gems in our weekly newsletter